DDInter1831 DDInter899
A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Tolmetin {u} (Compound) resembles {v} (Compound) Zolpidem
Tolmetin {u} (Compound) resembles {v} (Compound) Lumiracoxib
Tolmetin {u} (Compound) binds {v} (Gene) SLC22A6
Tolmetin {u} (Compound) upregulates {v} (Gene) MAL
Tolmetin {u} (Compound) palliates {v} (Disease) osteoarthritis
Tolmetin {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Tolmetin {u} (Compound) downregulates {v} (Gene) IARS2
Tolmetin {u} (Compound) causes {v} (Side Effect) Glossitis
Tolmetin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Famotidine
Tolmetin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abciximab
Tolmetin (Compound) resembles Zolpidem (Compound)
Tolmetin (Compound) resembles Lumiracoxib (Compound)
Tolmetin (Compound) binds SLC22A6 (Gene)
Tolmetin (Compound) upregulates MAL (Gene)
Tolmetin (Compound) palliates osteoarthritis (Disease)
Tolmetin (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class)
Tolmetin (Compound) downregulates IARS2 (Gene)
Tolmetin (Compound) causes Glossitis (Side Effect)
Tolmetin may cause a minor interaction that can limit clinical effects when taken with Famotidine
Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Abciximab